Please assess the completion status of the following clinical trial:

Trial Title: Immunogenicity, Safety and Lot to Lot Consistency of Novartis Meningococcal B Recombinant Vaccine When Administered With Routine Infant Vaccinations to Healthy Infants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy 2-month old infants (55-89 days, inclusive)~Exclusion Criteria:~* Prior vaccination with routine infant vaccines (Diphtheria, Tetanus, Pertussis, Polio, Haemophilus influenzae type b (Hib), and Pneumococcal antigens)~* Previous ascertained or suspected disease caused by N. meningitidis~* History of severe allergic reaction after previous vaccinations or hypersensitivity to any vaccine component;~* Any serious chronic or progressive disease~* Known or suspected impairment or alteration of the immune system

- Gender: ALL
- Minimum Age: 55 Days
- Maximum Age: 89 Days
- Healthy Volunteers: t

Study Arms:
- rMenB Lot1 (Type: EXPERIMENTAL): Subjects received one injection of rMenB+OMV NZ (Lot 1) at 2, 4, 6 months of age concomitantly with the routinely administered infant vaccines.
- rMenB Lot2 (Type: EXPERIMENTAL): Subjects received one injection of rMenB+OMV NZ (Lot 2) at 2, 4, 6 months of age concomitantly with the routinely administered infant vaccines.
- rMenB Lot3 (Type: EXPERIMENTAL): Subjects received one injection of rMenB+OMV NZ (Lot 3) at 2, 4, 6 months of age concomitantly with the routinely administered infant vaccines.
- Routine (Type: ACTIVE_COMPARATOR): Subjects received the routinely administered infant vaccines at 2, 4, 6 months of age.
- MenC + Routine (Type: ACTIVE_COMPARATOR): Subjects received the routinely administered infant vaccines and Men C vaccine at 2, 4 and 6 months of age.

Based on this trial design, predict the completion outcome and termination type (if applicable).